گیرنده آدنوزین A_2A

ADORA2A
ساختارهای موجود
PDB	جستجوی هم‌ساخت‌شناسی: PDBe RCSB
فهرست شناسه‌های PDB
	2YDO, 2YDV, 3EML, 3PWH, 3QAK, 3REY, 3RFM, 3UZA, 3UZC, 3VG9, 3VGA, 4EIY, 4UG2, 4UHR, 5IU4, 5IU7, 5IUA, 5IU8, 5IUB
معین‌کننده‌ها
نام‌های دیگر	ADORA2A, adenosine A2a receptor, A2aR, ADORA2, RDC8
شناسه‌های بیرونی	OMIM: 102776 MGI: 99402 HomoloGene: 20166 GeneCards: ADORA2A
موقعیت ژن (موش)
کروموزوم	کروموزوم ۱۰ (موش)
پایان	75,170,618 bp
الگوی گسترش RNA
	More reference expression data
هستی‌شناسی ژن
عملکرد ملکولی	• G protein-coupled adenosine receptor activity; • G protein-coupled receptor activity; • signal transducer activity; • GO:0001948، GO:0016582 پیوند پروتئینی; • identical protein binding; • enzyme binding; • alpha-actinin binding; • type 5 metabotropic glutamate receptor binding; • protein heterodimerization activity;
ترکیبات سلولی	• integral component of membrane; • membrane; • پوسته یاخته; • integral component of plasma membrane; • رشته‌های میانی; • دستگاه غشایی درونی; • GO:0097483، GO:0097481 postsynaptic density; • آسه; • دندریت; • axolemma; • asymmetric synapse; • presynaptic membrane; • neuronal cell body; • postsynaptic membrane; • presynaptic active zone; • integral component of postsynaptic membrane; • integral component of presynaptic membrane; • glutamatergic synapse; • Golgi membrane;
فرایند زیستی	• cAMP biosynthetic process; • G protein-coupled adenosine receptor signaling pathway; • sensory perception; • adenylate cyclase-modulating G protein-coupled receptor signaling pathway; • cell-cell signaling; • انعقاد خون; • blood circulation; • cellular defense response; • central nervous system development; • بیگانه‌خواری; • inflammatory response; • GO:0072468 ورارسانی پیام; • GO:0097285 مرگ برنامه‌ریزی‌شده یاخته; • synaptic transmission, dopaminergic; • response to amphetamine; • GO:0009373 regulation of transcription, DNA-templated; • negative regulation of protein kinase activity; • protein kinase C-activating G protein-coupled receptor signaling pathway; • synaptic transmission, cholinergic; • locomotory behavior; • negative regulation of cell population proliferation; • positive regulation of glutamate secretion; • positive regulation of acetylcholine secretion, neurotransmission; • regulation of norepinephrine secretion; • response to caffeine; • positive regulation of synaptic transmission, GABAergic; • synaptic transmission, glutamatergic; • positive regulation of urine volume; • positive regulation of renal sodium excretion; • negative regulation of locomotion; • اتساع عروق; • eating behavior; • negative regulation of vascular permeability; • negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; • response to alkaloid; • GO:1904089 negative regulation of neuron apoptotic process; • positive regulation of circadian sleep/wake cycle, sleep; • negative regulation of alpha-beta T cell activation; • astrocyte activation; • neuron projection morphogenesis; • positive regulation of protein secretion; • negative regulation of inflammatory response; • regulation of mitochondrial membrane potential; • membrane depolarization; • regulation of calcium ion transport; • positive regulation of synaptic transmission, glutamatergic; • excitatory postsynaptic potential; • inhibitory postsynaptic potential; • prepulse inhibition; • positive regulation of apoptotic signaling pathway; • G protein-coupled receptor signaling pathway; • adenylate cyclase-activating G protein-coupled receptor signaling pathway; • positive regulation of long-term synaptic potentiation; • regulation of synaptic vesicle exocytosis;
	منابع: آمیگو / کوئیک‌گو
هم‌ساخت‌شناسی
	135
	11540
	ENSG00000128271
	ENSMUSG00000020178
	P29274
	Q60613
	NM_001278497، NM_001278498، NM_001278499، NM_001278500، NR_103543، NR_103544 NM_000675، NM_001278497، NM_001278498، NM_001278499، NM_001278500، NR_103543، NR_103544
	XM_006513093، NM_001331095، NM_001331096، XM_030244829، XM_036155515 NM_009630، XM_006513093، NM_001331095، NM_001331096، XM_030244829، XM_036155515
	NP_001265426، NP_001265427، NP_001265428، NP_001265429 NP_000666، NP_001265426، NP_001265427، NP_001265428، NP_001265429
	NP_001318025، NP_033760، XP_006513156، XP_030100689، XP_036011408 NP_001318024، NP_001318025، NP_033760، XP_006513156، XP_030100689، XP_036011408
	ویکی‌داده
مشاهده/ویرایش انسان	مشاهده/ویرایش موش

گیرندهٔ آدنوزین A2A (انگلیسی: Adenosine A2A receptor) نوعی گیرنده آدنوزین است که در انسان توسط ژن «ADORA2A» کُدگذاری می‌شود.^[۴]^[۵]

عملکرد ویرایش

این پروتئین یکی از اعضای خانوادهٔ گیرنده‌های جفت‌شونده با پروتئین جی (GPCR) است که ۷ مارپیچ آلفا تراغشایی دارند. این پروتئین وظیفه‌اش را با فعال کردنِ آدنیلات سیکلاز و تحریک ساختِ آدنوزین مونوفسفات حلقه‌ای انجام می‌دهد و به میزان فراوانی در عقده‌های قاعده‌ای، دستگاه گردش خون، لنفوسیت‌های تی و پلاکت‌ها یافت می‌شود و یکی از اهداف مولکولیِ اصلیِ کافئین است که آنتاگونیست رقابتی آن محسوب می‌شود.^[۶]

اهمیت فیزیولوژیک و بالینی ویرایش

گیرنده A_2A به همراه گیرندهٔ A₁ در تنظیم نیازهای اکسیژنی عضلهٔ قلب و افزایش دادن جریان خون سرخرگ‌های کرونری از طریق گشاد کردن آنها نقش دارند. علاوه بر اینها، گیرنده A_2A می‌تواند موجب سرکوب سیستم ایمنی شده و بافت‌های بدن را در برابر التهاب محافظت کند.^[۷]

گیرنده A_2A در مغز هم بیان می‌شود و در آنجا نقش مهمی در تنظیم آزادسازی دوپامین و گلوتامات ایفا می‌کنند و به همین سبب ممکن است از اهداف درمانی بالقوه برای بی‌خوابی، درد، اختلال افسردگی عمده و بیماری پارکینسون باشد.^[۸]^[۹]^[۱۰]^[۱۱]^[۱۲]^[۱۳]^[۱۴]

لیگاندها ویرایش

چندین لیگاند انتخابی برای گیرنده A_2A ساخته شده‌است^[۱۵] که مصارف بالینی گوناگونی را در بر می‌گیرند.^[۱۶] پژوهش‌های پیشین بر روی عملکرد این گیرنده، بیشتر متمرکز بر آنتاگونیست‌های غیر اختصاصی همچون آمینوفیلین و نقش این گیرنده‌ها در قلب انسان بود که سبب شد چندین کارآزمایی تصادفی کنترل‌شده جهت استفاده از این داروها در درمان کندتپشی و ایست قلبی انجام شود.^[۱۷]^[۱۸]^[۱۹]^[۲۰]^[۲۱]^[۲۲]^[۲۳]

با این وجود، با ساخت لیگاندهای اختصاصی برای گیرنده A_2A در سال‌های اخیر، مصارف دیگری از آنها مورد توجه واقع شده‌است، به گونه‌ای که امروزه تمرکز پژوهشی فراوانی بر روی استفادهٔ احتمالی از آنتاگونیست‌های A_2A در درمان بیماری پارکینسون وجود دارد.^[۲۴]^[۲۵]^[۲۶]^[۲۷]

آگونیست‌ها ویرایش

آنتاگونیست‌ها ویرایش

منابع ویرایش

↑ ^۱٫۰ ^۱٫۱ ^۱٫۲ GRCm38: Ensembl release 89: ENSMUSG00000020178 - Ensembl, May 2017
↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑ Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, et al. (May 1989). "Selective amplification and cloning of four new members of the G protein-coupled receptor family". Science. 244 (4904): 569–72. Bibcode:1989Sci...244..569L. doi:10.1126/science.2541503. PMID 2541503.
↑ Libert F, Passage E, Parmentier M, Simons MJ, Vassart G, Mattei MG (September 1991). "Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor". Genomics. 11 (1): 225–7. doi:10.1016/0888-7543(91)90125-X. PMID 1662665.
↑ "Entrez Gene: ADORA2A adenosine A2A receptor".
↑ Ohta A, Sitkovsky M (2001). "Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage". Nature. 414 (6866): 916–20. Bibcode:2001Natur.414..916O. doi:10.1038/414916a. PMID 11780065. S2CID 4386419.
↑ Hack SP, Christie MJ (2003). "Adaptations in adenosine signaling in drug dependence: therapeutic implications". Critical Reviews in Neurobiology. 15 (3–4): 235–74. doi:10.1615/CritRevNeurobiol.v15.i34.30. PMID 15248812.
↑ Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA (December 2007). "Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications". Progress in Neurobiology. 83 (5): 293–309. doi:10.1016/j.pneurobio.2007.07.001. PMID 17826884. S2CID 27478825.
↑ Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (December 2007). "Adenosine A2A receptors and basal ganglia physiology". Progress in Neurobiology. 83 (5): 277–92. doi:10.1016/j.pneurobio.2007.05.001. PMC 2148496. PMID 17646043.
↑ Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, et al. (December 2007). "Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain". Progress in Neurobiology. 83 (5): 332–47. doi:10.1016/j.pneurobio.2007.04.002. PMC 2141681. PMID 17532111.
↑ Brown RM, Short JL (November 2008). "Adenosine A(2A) receptors and their role in drug addiction". The Journal of Pharmacy and Pharmacology. 60 (11): 1409–30. doi:10.1211/jpp/60.11.0001. PMID 18957161.
↑ Cunha RA, Ferré S, Vaugeois JM, Chen JF (2008). "Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders". Current Pharmaceutical Design. 14 (15): 1512–24. doi:10.2174/138161208784480090. PMC 2423946. PMID 18537674.
↑ Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, et al. (September 2008). "Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway". The Journal of Neuroscience. 28 (36): 9037–46. doi:10.1523/JNEUROSCI.1525-08.2008. PMC 2806668. PMID 18768698.
↑
- Ongini E, Monopoli A, Cacciari B, Baraldi PG (2001). "Selective adenosine A2A receptor antagonists". Farmaco. 56 (1–2): 87–90. doi:10.1016/S0014-827X(01)01024-2. PMID 11347973.
- Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, et al. (January 2002). "7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility". Journal of Medicinal Chemistry. 45 (1): 115–26. doi:10.1021/jm010924c. PMID 11754583.
- Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, et al. (March 2003). "Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists". Journal of Medicinal Chemistry. 46 (7): 1229–41. doi:10.1021/jm021023m. PMID 12646033.
- Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, et al. (December 2003). "Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease". Neurology. 61 (11 Suppl 6): S101-6. doi:10.1212/01.WNL.0000095581.20961.7D. PMID 14663021. S2CID 12327094.
- Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R (2003). "Medicinal chemistry of adenosine A2A receptor agonists". Current Topics in Medicinal Chemistry. 3 (4): 387–401. doi:10.2174/1568026033392282. PMID 12570757. Archived from the original on 2009-05-04. Retrieved 2018-10-02.
- Cacciari B, Pastorin G, Spalluto G (2003). "Medicinal chemistry of A2A adenosine receptor antagonists". Current Topics in Medicinal Chemistry. 3 (4): 403–11. doi:10.2174/1568026033392183. PMID 12570758. Archived from the original on 2009-05-04. Retrieved 2018-10-02.
- Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R (March 2007). "Highlights on the development of A(2A) adenosine receptor agonists and antagonists". ChemMedChem. 2 (3): 260–81. doi:10.1002/cmdc.200600193. PMID 17177231.
- Diniz C, Borges F, Santana L, Uriarte E, Oliveira JM, Gonçalves J, Fresco P (2008). "Ligands and therapeutic perspectives of adenosine A(2A) receptors". Current Pharmaceutical Design. 14 (17): 1698–722. doi:10.2174/138161208784746842. PMID 18673194. Archived from the original on 2009-05-04. Retrieved 2018-10-02.
- Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008). "A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists". Current Pharmaceutical Design. 14 (15): 1525–52. doi:10.2174/138161208784480081. PMID 18537675.
- Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2916–9. doi:10.1016/j.bmcl.2008.03.075. PMID 18406614.
- Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Giles PR, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2920–3. doi:10.1016/j.bmcl.2008.03.076. PMID 18407496.
- Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Jordan AM, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2924–9. doi:10.1016/j.bmcl.2008.03.072. PMID 18411049.
↑
- Sullivan GW (November 2003). "Adenosine A2A receptor agonists as anti-inflammatory agents". Current Opinion in Investigational Drugs. 4 (11): 1313–9. PMID 14758770.
- Lappas CM, Sullivan GW, Linden J (July 2005). "Adenosine A2A agonists in development for the treatment of inflammation". Expert Opinion on Investigational Drugs. 14 (7): 797–806. doi:10.1517/13543784.14.7.797. PMID 16022569. S2CID 19306651.
- El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology. 61 (11 Suppl 6): S82-7. doi:10.1212/01.WNL.0000095220.87550.F6. PMID 14663017. S2CID 36219448.
- Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL (January 2004). "Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors". Neuroscience Letters. 355 (1–2): 21–4. doi:10.1016/j.neulet.2003.10.040. PMID 14729225. S2CID 29253187.
- Takahashi RN, Pamplona FA, Prediger RD (January 2008). "Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies". Frontiers in Bioscience. 13 (13): 2614–32. doi:10.2741/2870. PMID 17981738.
- Lobato KR, Binfaré RW, Budni J, Rosa AO, Santos AR, Rodrigues AL (May 2008). "Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (4): 994–9. doi:10.1016/j.pnpbp.2008.01.012. PMID 18289757. S2CID 36068948.
↑ Burton JH, Mass M, Menegazzi JJ, Yealy DM (August 1997). "Aminophylline as an adjunct to standard advanced cardiac life support in prolonged cardiac arrest". Annals of Emergency Medicine. 30 (2): 154–8. doi:10.1016/S0196-0644(97)70134-3. PMID 9250637.
↑ Khoury MY, Moukarbel GV, Obeid MY, Alam SE (May 2001). "Effect of aminophylline on complete atrioventricular block with ventricular asystole following blunt chest trauma". Injury. 32 (4): 335–8. doi:10.1016/S0020-1383(00)00222-9. PMID 11325371.
↑ Mader TJ, Bertolet B, Ornato JP, Gutterman JM (October 2000). "Aminophylline in the treatment of atropine-resistant bradyasystole". Resuscitation. 47 (2): 105–12. doi:10.1016/S0300-9572(00)00234-3. PMID 11008148.
↑ Mader TJ, Smithline HA, Durkin L, Scriver G (March 2003). "A randomized controlled trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest". Academic Emergency Medicine. 10 (3): 192–7. doi:10.1197/aemj.10.3.192. PMID 12615581.
↑ Mader TJ, Gibson P (August 1997). "Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study". Resuscitation. 35 (1): 3–7. doi:10.1016/S0300-9572(97)01097-6. PMID 9259053.
↑ Perouansky M, Shamir M, Hershkowitz E, Donchin Y (July 1998). "Successful resuscitation using aminophylline in refractory cardiac arrest with asystole". Resuscitation. 38 (1): 39–41. doi:10.1016/S0300-9572(98)00079-3. PMID 9783508.
↑ Viskin S, Belhassen B, Roth A, Reicher M, Averbuch M, Sheps D, et al. (February 1993). "Aminophylline for bradyasystolic cardiac arrest refractory to atropine and epinephrine". Annals of Internal Medicine. 118 (4): 279–81. doi:10.7326/0003-4819-118-4-199302150-00006. PMID 8420445. S2CID 44883687.
↑ Jenner P (December 2003). "A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD". Neurology. 61 (11 Suppl 6): S32-8. doi:10.1212/01.WNL.0000095209.59347.79. PMID 14663007. S2CID 28897242.
↑ Mori A, Shindou T (December 2003). "Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists". Neurology. 61 (11 Suppl 6): S44-8. doi:10.1212/01.WNL.0000095211.71092.A0. PMID 14663009. S2CID 26827799.
↑ Pinna A, Wardas J, Simola N, Morelli M (November 2005). "New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists". Life Sciences. 77 (26): 3259–67. doi:10.1016/j.lfs.2005.04.029. PMID 15979104.
↑ Kelsey JE, Langelier NA, Oriel BS, Reedy C (January 2009). "The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat". Psychopharmacology. 201 (4): 529–39. doi:10.1007/s00213-008-1319-0. PMID 18791705. S2CID 24159282.
↑ ^۲۸٫۰ ^۲۸٫۱ ^۲۸٫۲ Jacobson KA, Gao ZG (March 2006). "Adenosine receptors as therapeutic targets". Nature Reviews. Drug Discovery. 5 (3): 247–64. doi:10.1038/nrd1983. PMC 3463109. PMID 16518376. table 1 lists affinities
↑ Burstein, Sumner (7 February 2015). "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation". Bioorganic & Medicinal Chemistry. 23 (7): 1377–1385. doi:10.1016/j.bmc.2015.01.059. PMID 25703248.
↑ Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P (September 2006). "The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets". European Journal of Pharmacology. 546 (1–3): 82–7. doi:10.1016/j.ejphar.2006.07.017. PMID 16925991.

مشارکت‌کنندگان ویکی‌پدیا. «Adenosine A2A receptor». در دانشنامهٔ ویکی‌پدیای انگلیسی، بازبینی‌شده در ۳ نوامبر ۲۰۲۰.

برای مطالعهٔ بیشتر ویرایش

Russo EB (August 2011). "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects". British Journal of Pharmacology. 163 (7): 1344–64. doi:10.1111/j.1476-5381.2011.01238.x. PMC 3165946. PMID 21749363.
Ongini E, Adami M, Ferri C, Bertorelli R (October 1997). "Adenosine A2A receptors and neuroprotection". Annals of the New York Academy of Sciences. 825 (1 Neuroprotecti): 30–48. Bibcode:1997NYASA.825...30O. doi:10.1111/j.1749-6632.1997.tb48412.x. PMID 9369973.
Furlong TJ, Pierce KD, Selbie LA, Shine J (September 1992). "Molecular characterization of a human brain adenosine A2 receptor". Brain Research. Molecular Brain Research. 15 (1–2): 62–6. doi:10.1016/0169-328X(92)90152-2. PMID 1331670.
Makujina SR, Sabouni MH, Bhatia S, Douglas FL, Mustafa SJ (October 1992). "Vasodilatory effects of adenosine A2 receptor agonists CGS 21680 and CGS 22492 in human vasculature". European Journal of Pharmacology. 221 (2–3): 243–7. doi:10.1016/0014-2999(92)90708-C. PMID 1426003.
Karlsten R, Gordh T, Post C (June 1992). "Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice". Pharmacology & Toxicology. 70 (6 Pt 1): 434–8. doi:10.1111/j.1600-0773.1992.tb00503.x. PMID 1438021.
Libert F, Passage E, Parmentier M, Simons MJ, Vassart G, Mattei MG (September 1991). "Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor". Genomics. 11 (1): 225–7. doi:10.1016/0888-7543(91)90125-X. PMID 1662665.
Martinez-Mir MI, Probst A, Palacios JM (1992). "Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease". Neuroscience. 42 (3): 697–706. doi:10.1016/0306-4522(91)90038-P. PMID 1835521. S2CID 23693441.
Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, et al. (May 1989). "Selective amplification and cloning of four new members of the G protein-coupled receptor family". Science. 244 (4904): 569–72. Bibcode:1989Sci...244..569L. doi:10.1126/science.2541503. PMID 2541503.
Kim J, Wess J, van Rhee AM, Schöneberg T, Jacobson KA (June 1995). "Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor". The Journal of Biological Chemistry. 270 (23): 13987–97. doi:10.1074/jbc.270.23.13987. PMC 3427751. PMID 7775460.
Szondy Z (December 1994). "Adenosine stimulates DNA fragmentation in human thymocytes by Ca(2+)-mediated mechanisms". The Biochemical Journal. 304. 304 ( Pt 3) (3): 877–85. doi:10.1042/bj3040877. PMC 1137415. PMID 7818494.
MacCollin M, Peterfreund R, MacDonald M, Fink JS, Gusella J (March 1994). "Mapping of a human A2a adenosine receptor (ADORA2) to chromosome 22". Genomics. 20 (2): 332–3. doi:10.1006/geno.1994.1181. PMID 8020991.
Nonaka H, Ichimura M, Takeda M, Nonaka Y, Shimada J, Suzuki F, et al. (May 1994). "KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist". European Journal of Pharmacology. 267 (3): 335–41. doi:10.1016/0922-4106(94)90159-7. PMID 8088373.
Iwamoto T, Umemura S, Toya Y, Uchibori T, Kogi K, Takagi N, Ishii M (March 1994). "Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells". Biochemical and Biophysical Research Communications. 199 (2): 905–10. doi:10.1006/bbrc.1994.1314. PMID 8135838.
Salmon JE, Brogle N, Brownlie C, Edberg JC, Kimberly RP, Chen BX, Erlanger BF (September 1993). "Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function". Journal of Immunology. 151 (5): 2775–85. PMID 8360491.
Peterfreund RA, MacCollin M, Gusella J, Fink JS (January 1996). "Characterization and expression of the human A2a adenosine receptor gene". Journal of Neurochemistry. 66 (1): 362–8. doi:10.1046/j.1471-4159.1996.66010362.x. PMID 8522976.
Le F, Townsend-Nicholson A, Baker E, Sutherland GR, Schofield PR (June 1996). "Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A". Biochemical and Biophysical Research Communications. 223 (2): 461–7. doi:10.1006/bbrc.1996.0916. PMID 8670304.
Jiang Q, Van Rhee AM, Kim J, Yehle S, Wess J, Jacobson KA (September 1996). "Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition". Molecular Pharmacology. 50 (3): 512–21. PMC 3418326. PMID 8794889.
Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, et al. (August 1997). "Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor". Nature. 388 (6643): 674–8. Bibcode:1997Natur.388..674L. doi:10.1038/41771. PMID 9262401. S2CID 2662174.
Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV (March 1999). "Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies". Molecular Pharmacology. 55 (3): 614–24. PMID 10051547.
Borgland SL, Castañón M, Spevak W, Parkinson FE (December 1998). "Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene". Canadian Journal of Physiology and Pharmacology. 76 (12): 1132–8. doi:10.1139/cjpp-76-12-1132. PMID 10326835.

پیوند به بیرون ویرایش

مکان ژنوم ADORA2A انسانی و صفحهٔ جزئیات ژنی ADORA2A در سامانه جستجوی بانک ژنی دانشگاه کالیفرنیا، سانتا کروز.

[refGRCm38Ensembl-1] ۱٫۰ ^۱٫۱ ^۱٫۲ GRCm38: Ensembl release 89: ENSMUSG00000020178 - Ensembl, May 2017

[2] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[3] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid2541503-4] Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, et al. (May 1989). "Selective amplification and cloning of four new members of the G protein-coupled receptor family". Science. 244 (4904): 569–72. Bibcode:1989Sci...244..569L. doi:10.1126/science.2541503. PMID 2541503.

[pmid1662665-5] Libert F, Passage E, Parmentier M, Simons MJ, Vassart G, Mattei MG (September 1991). "Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor". Genomics. 11 (1): 225–7. doi:10.1016/0888-7543(91)90125-X. PMID 1662665.

[entrez-6] "Entrez Gene: ADORA2A adenosine A2A receptor".

[pmid11780065-7] Ohta A, Sitkovsky M (2001). "Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage". Nature. 414 (6866): 916–20. Bibcode:2001Natur.414..916O. doi:10.1038/414916a. PMID 11780065. S2CID 4386419.

[pmid15248812-8] Hack SP, Christie MJ (2003). "Adaptations in adenosine signaling in drug dependence: therapeutic implications". Critical Reviews in Neurobiology. 15 (3–4): 235–74. doi:10.1615/CritRevNeurobiol.v15.i34.30. PMID 15248812.

[pmid17826884-9] Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA (December 2007). "Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications". Progress in Neurobiology. 83 (5): 293–309. doi:10.1016/j.pneurobio.2007.07.001. PMID 17826884. S2CID 27478825.

[pmid17646043-10] Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (December 2007). "Adenosine A2A receptors and basal ganglia physiology". Progress in Neurobiology. 83 (5): 277–92. doi:10.1016/j.pneurobio.2007.05.001. PMC 2148496. PMID 17646043.

[pmid17532111-11] Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, et al. (December 2007). "Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain". Progress in Neurobiology. 83 (5): 332–47. doi:10.1016/j.pneurobio.2007.04.002. PMC 2141681. PMID 17532111.

[pmid18957161-12] Brown RM, Short JL (November 2008). "Adenosine A(2A) receptors and their role in drug addiction". The Journal of Pharmacy and Pharmacology. 60 (11): 1409–30. doi:10.1211/jpp/60.11.0001. PMID 18957161.

[pmid18537674-13] Cunha RA, Ferré S, Vaugeois JM, Chen JF (2008). "Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders". Current Pharmaceutical Design. 14 (15): 1512–24. doi:10.2174/138161208784480090. PMC 2423946. PMID 18537674.

[pmid18768698-14] Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, et al. (September 2008). "Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway". The Journal of Neuroscience. 28 (36): 9037–46. doi:10.1523/JNEUROSCI.1525-08.2008. PMC 2806668. PMID 18768698.

[ligands-15] 
Ongini E, Monopoli A, Cacciari B, Baraldi PG (2001). "Selective adenosine A2A receptor antagonists". Farmaco. 56 (1–2): 87–90. doi:10.1016/S0014-827X(01)01024-2. PMID 11347973.

Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, et al. (January 2002). "7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility". Journal of Medicinal Chemistry. 45 (1): 115–26. doi:10.1021/jm010924c. PMID 11754583.

Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, et al. (March 2003). "Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists". Journal of Medicinal Chemistry. 46 (7): 1229–41. doi:10.1021/jm021023m. PMID 12646033.

Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, et al. (December 2003). "Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease". Neurology. 61 (11 Suppl 6): S101-6. doi:10.1212/01.WNL.0000095581.20961.7D. PMID 14663021. S2CID 12327094.

Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R (2003). "Medicinal chemistry of adenosine A2A receptor agonists". Current Topics in Medicinal Chemistry. 3 (4): 387–401. doi:10.2174/1568026033392282. PMID 12570757. Archived from the original on 2009-05-04. Retrieved 2018-10-02.

Cacciari B, Pastorin G, Spalluto G (2003). "Medicinal chemistry of A2A adenosine receptor antagonists". Current Topics in Medicinal Chemistry. 3 (4): 403–11. doi:10.2174/1568026033392183. PMID 12570758. Archived from the original on 2009-05-04. Retrieved 2018-10-02.

Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R (March 2007). "Highlights on the development of A(2A) adenosine receptor agonists and antagonists". ChemMedChem. 2 (3): 260–81. doi:10.1002/cmdc.200600193. PMID 17177231.

Diniz C, Borges F, Santana L, Uriarte E, Oliveira JM, Gonçalves J, Fresco P (2008). "Ligands and therapeutic perspectives of adenosine A(2A) receptors". Current Pharmaceutical Design. 14 (17): 1698–722. doi:10.2174/138161208784746842. PMID 18673194. Archived from the original on 2009-05-04. Retrieved 2018-10-02.

Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008). "A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists". Current Pharmaceutical Design. 14 (15): 1525–52. doi:10.2174/138161208784480081. PMID 18537675.

Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2916–9. doi:10.1016/j.bmcl.2008.03.075. PMID 18406614.

Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Giles PR, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2920–3. doi:10.1016/j.bmcl.2008.03.076. PMID 18407496.

Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Jordan AM, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2924–9. doi:10.1016/j.bmcl.2008.03.072. PMID 18411049.

[16] Ongini E, Monopoli A, Cacciari B, Baraldi PG (2001). "Selective adenosine A2A receptor antagonists". Farmaco. 56 (1–2): 87–90. doi:10.1016/S0014-827X(01)01024-2. PMID 11347973.

[17] Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, et al. (January 2002). "7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility". Journal of Medicinal Chemistry. 45 (1): 115–26. doi:10.1021/jm010924c. PMID 11754583.

[18] Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, et al. (March 2003). "Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists". Journal of Medicinal Chemistry. 46 (7): 1229–41. doi:10.1021/jm021023m. PMID 12646033.

[19] Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, et al. (December 2003). "Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease". Neurology. 61 (11 Suppl 6): S101-6. doi:10.1212/01.WNL.0000095581.20961.7D. PMID 14663021. S2CID 12327094.

[20] Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R (2003). "Medicinal chemistry of adenosine A2A receptor agonists". Current Topics in Medicinal Chemistry. 3 (4): 387–401. doi:10.2174/1568026033392282. PMID 12570757. Archived from the original on 2009-05-04. Retrieved 2018-10-02.

[21] Cacciari B, Pastorin G, Spalluto G (2003). "Medicinal chemistry of A2A adenosine receptor antagonists". Current Topics in Medicinal Chemistry. 3 (4): 403–11. doi:10.2174/1568026033392183. PMID 12570758. Archived from the original on 2009-05-04. Retrieved 2018-10-02.

[22] Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R (March 2007). "Highlights on the development of A(2A) adenosine receptor agonists and antagonists". ChemMedChem. 2 (3): 260–81. doi:10.1002/cmdc.200600193. PMID 17177231.

[23] Diniz C, Borges F, Santana L, Uriarte E, Oliveira JM, Gonçalves J, Fresco P (2008). "Ligands and therapeutic perspectives of adenosine A(2A) receptors". Current Pharmaceutical Design. 14 (17): 1698–722. doi:10.2174/138161208784746842. PMID 18673194. Archived from the original on 2009-05-04. Retrieved 2018-10-02.

[24] Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008). "A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists". Current Pharmaceutical Design. 14 (15): 1525–52. doi:10.2174/138161208784480081. PMID 18537675.

[25] Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2916–9. doi:10.1016/j.bmcl.2008.03.075. PMID 18406614.

[26] Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Giles PR, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2920–3. doi:10.1016/j.bmcl.2008.03.076. PMID 18407496.

[27] Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Jordan AM, et al. (May 2008). "Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines". Bioorganic & Medicinal Chemistry Letters. 18 (9): 2924–9. doi:10.1016/j.bmcl.2008.03.072. PMID 18411049.

[theraputic-16] 
Sullivan GW (November 2003). "Adenosine A2A receptor agonists as anti-inflammatory agents". Current Opinion in Investigational Drugs. 4 (11): 1313–9. PMID 14758770.

Lappas CM, Sullivan GW, Linden J (July 2005). "Adenosine A2A agonists in development for the treatment of inflammation". Expert Opinion on Investigational Drugs. 14 (7): 797–806. doi:10.1517/13543784.14.7.797. PMID 16022569. S2CID 19306651.

El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology. 61 (11 Suppl 6): S82-7. doi:10.1212/01.WNL.0000095220.87550.F6. PMID 14663017. S2CID 36219448.

Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL (January 2004). "Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors". Neuroscience Letters. 355 (1–2): 21–4. doi:10.1016/j.neulet.2003.10.040. PMID 14729225. S2CID 29253187.

Takahashi RN, Pamplona FA, Prediger RD (January 2008). "Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies". Frontiers in Bioscience. 13 (13): 2614–32. doi:10.2741/2870. PMID 17981738.

Lobato KR, Binfaré RW, Budni J, Rosa AO, Santos AR, Rodrigues AL (May 2008). "Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (4): 994–9. doi:10.1016/j.pnpbp.2008.01.012. PMID 18289757. S2CID 36068948.

[29] Sullivan GW (November 2003). "Adenosine A2A receptor agonists as anti-inflammatory agents". Current Opinion in Investigational Drugs. 4 (11): 1313–9. PMID 14758770.

[30] Lappas CM, Sullivan GW, Linden J (July 2005). "Adenosine A2A agonists in development for the treatment of inflammation". Expert Opinion on Investigational Drugs. 14 (7): 797–806. doi:10.1517/13543784.14.7.797. PMID 16022569. S2CID 19306651.

[31] El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology. 61 (11 Suppl 6): S82-7. doi:10.1212/01.WNL.0000095220.87550.F6. PMID 14663017. S2CID 36219448.

[32] Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL (January 2004). "Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors". Neuroscience Letters. 355 (1–2): 21–4. doi:10.1016/j.neulet.2003.10.040. PMID 14729225. S2CID 29253187.

[33] Takahashi RN, Pamplona FA, Prediger RD (January 2008). "Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies". Frontiers in Bioscience. 13 (13): 2614–32. doi:10.2741/2870. PMID 17981738.

[34] Lobato KR, Binfaré RW, Budni J, Rosa AO, Santos AR, Rodrigues AL (May 2008). "Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (4): 994–9. doi:10.1016/j.pnpbp.2008.01.012. PMID 18289757. S2CID 36068948.

[pmid9250637-17] Burton JH, Mass M, Menegazzi JJ, Yealy DM (August 1997). "Aminophylline as an adjunct to standard advanced cardiac life support in prolonged cardiac arrest". Annals of Emergency Medicine. 30 (2): 154–8. doi:10.1016/S0196-0644(97)70134-3. PMID 9250637.

[pmid11325371-18] Khoury MY, Moukarbel GV, Obeid MY, Alam SE (May 2001). "Effect of aminophylline on complete atrioventricular block with ventricular asystole following blunt chest trauma". Injury. 32 (4): 335–8. doi:10.1016/S0020-1383(00)00222-9. PMID 11325371.

[pmid11008148-19] Mader TJ, Bertolet B, Ornato JP, Gutterman JM (October 2000). "Aminophylline in the treatment of atropine-resistant bradyasystole". Resuscitation. 47 (2): 105–12. doi:10.1016/S0300-9572(00)00234-3. PMID 11008148.

[pmid12615581-20] Mader TJ, Smithline HA, Durkin L, Scriver G (March 2003). "A randomized controlled trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest". Academic Emergency Medicine. 10 (3): 192–7. doi:10.1197/aemj.10.3.192. PMID 12615581.

[pmid9259053-21] Mader TJ, Gibson P (August 1997). "Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study". Resuscitation. 35 (1): 3–7. doi:10.1016/S0300-9572(97)01097-6. PMID 9259053.

[pmid9783508-22] Perouansky M, Shamir M, Hershkowitz E, Donchin Y (July 1998). "Successful resuscitation using aminophylline in refractory cardiac arrest with asystole". Resuscitation. 38 (1): 39–41. doi:10.1016/S0300-9572(98)00079-3. PMID 9783508.

[pmid8420445-23] Viskin S, Belhassen B, Roth A, Reicher M, Averbuch M, Sheps D, et al. (February 1993). "Aminophylline for bradyasystolic cardiac arrest refractory to atropine and epinephrine". Annals of Internal Medicine. 118 (4): 279–81. doi:10.7326/0003-4819-118-4-199302150-00006. PMID 8420445. S2CID 44883687.

[pmid14663007-24] Jenner P (December 2003). "A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD". Neurology. 61 (11 Suppl 6): S32-8. doi:10.1212/01.WNL.0000095209.59347.79. PMID 14663007. S2CID 28897242.

[pmid14663009-25] Mori A, Shindou T (December 2003). "Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists". Neurology. 61 (11 Suppl 6): S44-8. doi:10.1212/01.WNL.0000095211.71092.A0. PMID 14663009. S2CID 26827799.

[pmid15979104-26] Pinna A, Wardas J, Simola N, Morelli M (November 2005). "New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists". Life Sciences. 77 (26): 3259–67. doi:10.1016/j.lfs.2005.04.029. PMID 15979104.

[pmid18791705-27] Kelsey JE, Langelier NA, Oriel BS, Reedy C (January 2009). "The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat". Psychopharmacology. 201 (4): 529–39. doi:10.1007/s00213-008-1319-0. PMID 18791705. S2CID 24159282.

[pmid16518376-28] ۲۸٫۰ ^۲۸٫۱ ^۲۸٫۲ Jacobson KA, Gao ZG (March 2006). "Adenosine receptors as therapeutic targets". Nature Reviews. Drug Discovery. 5 (3): 247–64. doi:10.1038/nrd1983. PMC 3463109. PMID 16518376. table 1 lists affinities

[29] Burstein, Sumner (7 February 2015). "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation". Bioorganic & Medicinal Chemistry. 23 (7): 1377–1385. doi:10.1016/j.bmc.2015.01.059. PMID 25703248.

[pmid16925991-30] Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P (September 2006). "The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets". European Journal of Pharmacology. 546 (1–3): 82–7. doi:10.1016/j.ejphar.2006.07.017. PMID 16925991.

[۴]

[۵]

[۱]

[۲]

[۳]

[۶]

[۷]

[۸]

[۹]

[۱۰]

[۱۱]

[۱۲]

[۱۳]

[۱۴]

[۱۵]

[۱۶]

[۱۷]

[۱۸]

[۱۹]

[۲۰]

[۲۱]

[۲۲]

[۲۳]

[۲۴]

[۲۵]

[۲۶]

[۲۷]

[۲۸]

[۲۹]

[۳۰]

گیرنده آدنوزین A2A